V.I. Zaytseva, Yu.A. Luchinskaya Betaxolol clinical trial in patients with ischemic heart disease and arrhythmias.

We studied antianginal effect of betaxolol, its influence on arrhythmias, carbohydrate and lipid exchange (including the level of free fat acids in peripheral blood (FFA)) in 30 patients with ischemic heart disease and arrhythmias. This trial proceeded 4 months: two months of control period with diltiazem treatment, and further two months of betaxolol treatment with average dose 7.0±1.74 mg daily. According to ambulatory Holter ECG
monitoring negative chronotropic effect was registered only under betaxolol treatment: heart rate decreased by 15.6 % after 2-month treatment. This was accompanied by significant antiischemic action of the drug: ST
depression duration diminished by 77.3 %. Frequency of supraventricular extrasystoles diminished significantly after betaxolol treatment, while the amount of runs of supraventricular tachycardia and ventricular extrasystoles demonstrated gradual, statistically decline at all three periods of investigation. We didn’t find any lipid changes during four months of observation. The initial blood FFA values exceeded normal that was considered as an additional pathogenetic factor of IHD progression. During treatment period this parameter demonstrated a steady tendency to the decline, with significant decrease at the 4-th month. During the control period the average blood insulin demonstrated significant increase by 13.5 % and average blood glucose – decrease by 6.1 %. Two-months betaxolol treatment caused return of blood glucose to the initial value, while blood insulin did not significantly change, and HOMA index demonstrated tendency to decline.

Full article